Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer

Theodoropoulos, Panayiotis A.; Polioudaki, Hara; Agelaki, Sofia; Kallergi, Galatea; Saridaki, Zacharenia; Mavroudis, Dimitris; Georgoulias, Vassilis

doi:10.1016/j.canlet.2009.06.027

Cited by 268 publications

(187 citation statements)

References 28 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…However, it is likely that only a restricted fraction of them may migrate through the blood stream, colonize other tissues and initiate a new tumor mass in another location, thereby giving rise to metastatic lesions. As shown for breast cancer, these cells are now largely believed to be compatible with CSCs (Ross and Slodkowska, 2009;Theodoropoulos et al, 2009). These findings confer key relevance to CSCs also in the topic of circulating tumor cells and in the differential diagnosis of localized or premetastatic disease.…”

Section: Cscs and Their Possible Implications For The Development Of mentioning

confidence: 68%

Lung cancer stem cells: tools and targets to fight lung cancer

2010

View full text Add to dashboard Cite

Section: Cscs and Their Possible Implications For The Development Of mentioning

confidence: 68%

Lung cancer stem cells: tools and targets to fight lung cancer

2010

View full text Add to dashboard Cite

“…To date, several lines of evidence support the idea that CSCs contribute to both therapy resistance and metastatic dissemination. [25][26][27][28][29] However, to validate these ideas, progress must be made on the molecular mechanisms governing such processes, starting with the identification of genes and signals that define CSCs properties. The Hippo transducer TAZ has been shown to endow CSC properties to non-CSCs cells in BC cell lines.…”

Section: Discussionmentioning

confidence: 99%

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

et al. 2014

View full text Add to dashboard Cite

Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential. Gene-expression profile studies comparing metastagenic and non-metastagenic cells identified TAZ, a transducer of the Hippo pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis, thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates TAZ as a novel biomarker and a possible therapeutic target for BC.

show abstract

“…For patient's prognosis, these parameters of tumor spread could be more relevant than the likelihood of a metastasis from lymph nodes [125,126]. Therefore we need effective treatment strategies for these probably stem cell like tumor cells [127][128][129][130]. In conclusion, there is increasing doubt, that lymph node metastasis are able to metastasize.…”

Section: Do Lymph Node Metastases Metastasize?mentioning

confidence: 99%

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Gerber

Heintze

Stubert

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Evaluation of axillary lymph node status by sentinel lymph node biopsy (SLNB) and complete axillary lymph node dissection (ALND) are an inherent part of breast cancer treatment. Increased understanding of tumor biology has changed the prognostic and therapeutic impact of lymph node status. Non-invasive imaging techniques like axillary ultrasound, FDG-PET or MRI revealed moderate sensitivity and high specificity in evaluation of lymph node status. Therefore, they are not sufficient for lymph node staging. Otherwise the impact of remaining micrometastases and even macrometastases for prognosis and treatment decisions is overestimated.Considering tumor biology, the distinction of axillary metastases in isolated tumor cells (ITC, pN0[i+]); micrometastases (pN1mi), and macrometastases (pN1a)

show abstract

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer

Cited by 268 publications

References 28 publications

Lung cancer stem cells: tools and targets to fight lung cancer

Lung cancer stem cells: tools and targets to fight lung cancer

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Contact Info

Product

Resources

About